eLetters

117 e-Letters

published between 2010 and 2013

  • In response: "Paying attention to carpal tunnel contents lesions: ultrasound for evaluation of carpal tunnel syndrome"
    Christian Dejaco

    Dear Editor,

    our and several previous studies demonstrated a high diagnostic value of ultrasound for carpal tunnel syndrome (CTS) [1,2]. Among the various abnormalities within the carpal tunnel reported, the increase of the cross -sectional area (CSA) of the median nerve is the most commonly studied ultrasound abnormality [3]. In addition, ultrasound allows the identification of secondary causes of CTS such as sy...

    Show More
  • Reply to: Which B-cell subset should we target in lupus?
    Gururaj Arumugakani

    Dear Editor,

    We read with interest the editorial by Ferraccioli and Houssiau proposing the specific targeting of long lived plasma cells (PCs) in human lupus nephritis (LN) [1]. The authors present a cogent summary of experiments showing that long-lived PCs alone are sufficient to induce murine LN, and that targeting of PCs in these models is successful. However, we believe that clinical experience with the treatme...

    Show More
  • The classification criteria for Sjogren's syndrome: issues for their improvement from the study of a large Italian cohort of patients
    Luca Quartuccio

    Dear Editor,

    we read with great interest the article by Rasmussen et al. [1] which compared the performance of the new ACR [2] and the AECG [3] classification criteria for Sjogren's syndrome (SS) showing that they led to similar results when applied to a well-characterized cohort of patients with sicca symptoms. More specifically, no clear evidence for an increased value of the new ACR criteria [2] over the old AEC...

    Show More
  • When is it not ethical to withhold treatment for rheumatoid arthritis?
    Yusuf Yazici

    Dear Editor

    I read with interest the study by Takeuchi et al (1) looking at the role of monotherapy golimumab in Japanese rheumatoid arthritis (RA) patients, who had active disease despite disease modifying anti-rheumatic drug (DMARD) therapy. Inclusion criteria for the study stipulated that patients have 2/3 criteria which were: elevated inflammatory markers, erosions on radiograph or positive serology, in additio...

    Show More
  • Drug survival on TNF inhibitors: 2003-2004 data from Italian national register (GISEA Register)
    Florenzo Iannone

    Dear Editor,

    We read with interest the findings of the paper by Neovius et al recently published on Annals of the Rheumatic Diseases 1 who retrospectively studied the drug survival on TNF-alpha blockers in patients with rheumatoid arthritis (RA) in real life settings. The primary endpoint of their analysis was to assess the drug discontinuation rates in RA patients starting a first ever TNF-alpha inhibitor, and to...

    Show More
  • Paying attention to carpal tunnel contents lesions: ultrasound for evaluation of carpal tunnel syndrome
    Jiaan Zhu

    Dear Editor,

    We read with great interest the report by Dejaco and co-authors related to diagnosis of carpal tunnel syndrome (CTS) by ultrasound [1]. Dejaco et al. compared ultrasound measurement of median nerve cross- sectional area (CSA) at different anatomical landmarks in great detail and evaluated the value of intranerval power Doppler signals for CTS diagnosis. It provided a good data support for the ultrasonic...

    Show More
  • Response to:Comorbidities in a Mexican Mestizo cohort with established rheumatoid arthritis
    Maxime Dougados

    Dear Editor,

    On behalf of the investigators of the COMORA study, we would like to congratulate for the study you have conducted in Mexican mestizo patients. The results observed are totally in accordance with the results observed in the COMORA study that is: 1/ a relevant percentage of rheumatoid arthritis patients with comorbidities and 2/ a huge inter-country variability.

    We would like to echo our Me...

    Show More
  • The concept of axial spondyloarthritis. Lessons from the INFAST study
    Henning Zeidler

    Dear Editor,

    Sieper et al. evaluated whether combination therapy with Infliximab (IFX) and naproxen (NPX) was superior to treatment with NPX alone in patients who had active moderate-to-severe early (disease duration under 3 years) active axial spondyloarthritis (SpA) and who were naive to nonsteroidal anti-inflammatory drugs (NSAIDs) or had only been treated with a submaximal dose of NSAIDs (1). This study is the...

    Show More
  • Comorbidities in a Mexican Mestizo cohort with established rheumatoid arthritis
    David Vega-Morales

    Dear editor,

    In the study recently published in the Annals of Rheumatic Diseases, Dougados et al. [1] evaluated the prevalence of comorbidities and compared their management in Rheumatoid Arthritis (RA) patients from different countries. We know that RA is a chronic autoimmune disease characterized by chronic inflammation, progressive deterioration of joint function, increased comorbidity and mortality; RA pati...

    Show More
  • Response to: Detection of anti-nuclear antibodies. Added-value of solid phase assay?
    Nancy Agmon-Levin

    Dear Editor,

    We have read the letter by Bossuyt X. and Fieuws S. entitled "Detection of anti-nuclear antibodies, added-value of solid phase assay?" with great interest (1). In this letter the authors described a comparison between anti-nuclear antibodies (ANA) performed by indirect immunofluorescent assay(IIFA) and by an automated method (fluoroenzymeimmunoassay; EliA CTD screen, Thermo Fisher) using samples obtai...

    Show More

Pages